8037 — China Biotech Services Holdings Income Statement
0.000.00%
Last trade - 00:00- HK$936.70m
- HK$1.11bn
- HK$70.51m
Annual income statement for China Biotech Services Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 656 | 624 | 1,852 | 212 | 70.5 |
| Cost of Revenue | |||||
| Gross Profit | 339 | 358 | 1,101 | 34.3 | -4.94 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 458 | 437 | 1,004 | 359 | 282 |
| Operating Profit | 197 | 187 | 848 | -147 | -212 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 203 | 181 | 863 | -142 | -253 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 168 | 133 | 706 | -141 | -252 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 30.2 | 19.4 | 258 | -95.4 | -198 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 30.2 | 19.4 | 258 | -95.4 | -198 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.034 | 0.022 | 0.271 | -0.082 | -0.149 |
| Dividends per Share |